Quebe-Fehling E - Search Results

1

Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease.

Thomson NC, Angus R, Quebe-Fehling E, Brambilla R. Thomson NC, et al. Respir Med. 1998 Mar;92(3):562-7. doi: 10.1016/s0954-6111(98)90309-2. Respir Med. 1998. PMID: 9692123 Free article. Clinical Trial.

2

A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease.

Vervloet D, Ekström T, Pela R, Duce Gracia F, Kopp C, Silvert BD, Quebe-Fehling E, Della Cioppa G, Di Benedetto G. Vervloet D, et al. Respir Med. 1998 Jun;92(6):836-42. doi: 10.1016/s0954-6111(98)90385-7. Respir Med. 1998. PMID: 9850367 Free article. Clinical Trial.

3

The duration of action of inhaled formoterol dry powder.

Quebe-Fehling E, Brambilla R, Bromly CL, Fishwick K, Walters EH, Hendrick DJ. Quebe-Fehling E, et al. Br J Clin Pract. 1996 Dec;50(8):446-9. Br J Clin Pract. 1996. PMID: 9039716 Clinical Trial.

4

Comparative bioequivalence studies with Estradot and Menorest transdermal systems.

Hossain M, Quebe-Fehling E, Sergejew T, Schmidt G, Skerjanec A, Cohen A, Krinsky L, Ibarra de Palacios P. Hossain M, et al. Maturitas. 2003 Nov 20;46(3):187-98. doi: 10.1016/s0378-5122(03)00190-7. Maturitas. 2003. PMID: 14585521 Clinical Trial.

5

Dose proportionality study of four doses of an estradiol transdermal system, Estradot.

Hossain M, Quebe-Fehling E, Sergejew T, Schmidt G, Skerjanec A, Ibarra de Palacios P, Krinsky L. Hossain M, et al. Maturitas. 2003 Nov 20;46(3):173-85. doi: 10.1016/s0378-5122(03)00189-0. Maturitas. 2003. PMID: 14585520 Clinical Trial.

6

Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study.

Aydinok Y, Porter JB, Piga A, Elalfy M, El-Beshlawy A, Kilinç Y, Viprakasit V, Yesilipek A, Habr D, Quebe-Fehling E, Pennell DJ. Aydinok Y, et al. Among authors: quebe fehling e. Eur J Haematol. 2015 Sep;95(3):244-53. doi: 10.1111/ejh.12487. Epub 2015 Jan 8. Eur J Haematol. 2015. PMID: 25418187 Free article. Clinical Trial.

7

Evaluation of irritation and sensitisation of two 50 microg/day oestrogen patches.

Toole J, Silagy S, Maric A, Fath B, Quebe-Fehling E, Ibarra de Palacios P, Laurin L, Giguere M. Toole J, et al. Maturitas. 2002 Dec 10;43(4):257-63. doi: 10.1016/s0378-5122(02)00189-5. Maturitas. 2002. PMID: 12468134 Clinical Trial.

8

Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women.

Rubinacci A, Peruzzi E, Modena AB, Zanardi E, Andrei B, De Leo V, Pansini FS, Quebe-Fehling E, de Palacios PI. Rubinacci A, et al. Menopause. 2003 May-Jun;10(3):241-9. doi: 10.1097/00042192-200310030-00012. Menopause. 2003. PMID: 12792297 Clinical Trial.

9

Comparative study to evaluate skin irritation and adhesion of Estradot and Climara in healthy postmenopausal women.

Ibarra de Palacios P, Schmidt G, Sergejew T, Quebe-Fehling E, Lockhart L, Krinsky L. Ibarra de Palacios P, et al. Climacteric. 2002 Dec;5(4):383-9. doi: 10.1080/713605305. Climacteric. 2002. PMID: 12626218 Clinical Trial.

10

Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy.

Zinner N, Kobashi KC, Ebinger U, Viegas A, Egermark M, Quebe-Fehling E, Koochaki P. Zinner N, et al. Among authors: quebe fehling e. Int J Clin Pract. 2008 Nov;62(11):1664-74. doi: 10.1111/j.1742-1241.2008.01893.x. Epub 2008 Sep 22. Int J Clin Pract. 2008. PMID: 18811599 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results